CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)

Pantothenate Kinase-Associated Neurodegeneration Clinical Trial

Official title:
A Phase 2 Study of a Vitamin Metabolite for PKAN

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to learn more about how people with the condition pantothenate kinase-associated neurodegeneration (PKAN) respond to a specialized study product. We are hoping to find out if the study product is safe, what effects-good and bad-the study product causes, and whether the study product changes certain measures of disease in PKAN.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Nerve Degeneration
Pantothenate Kinase-Associated Neurodegeneration

Clinical Trial Details

NCT number	NCT04182763
Study type	Interventional
Source	Oregon Health and Science University
Contact
Status	Active, not recruiting
Phase	N/A
Start date	December 4, 2019
Completion date	January 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02174848` - Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration	Phase 3
Terminated	`NCT03041116` - Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants	Phase 3
Completed	`NCT01741532` - Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)	Phase 3
No longer available	`NCT02635841` - Compassionate Use of Deferiprone in Patients With PKAN